Educational guide
Difference Between LL-37 and VIP — Real Peptides
Difference Between LL-37 and VIP — Real Peptides Research from Johns Hopkins identified LL-37 as the only human cathelicidin antimicrobial peptide, expressed at mucosal surfaces and in neutrophils as a first-line innate immune defense. Meanwhile, VIP (vasoacti
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Difference Between LL-37 and VIP — Real Peptides
Research from Johns Hopkins identified LL-37 as the only human cathelicidin antimicrobial peptide, expressed at mucosal surfaces and in neutrophils as a first-line innate immune defense. Meanwhile, VIP (vasoactive intestinal peptide) functions as a 28-amino-acid neuropeptide regulating inflammation, smooth muscle relaxation, and circadian rhythm through entirely separate receptor pathways. The difference between LL-37 and VIP isn't subtle. It's foundational.
We've worked with researchers studying both peptides across immunology, neuroscience, and inflammatory disease models. The confusion stems from their shared presence in immune regulation literature, but the mechanisms, target tissues, and experimental protocols for each couldn't be more distinct.
What is the difference between LL-37 and VIP?
LL-37 is a 37-amino-acid antimicrobial peptide derived from the hCAP18 precursor protein, functioning through direct pathogen membrane disruption and immune cell recruitment. VIP is a 28-amino-acid neuropeptide that binds VPAC1 and VPAC2 receptors to suppress pro-inflammatory cytokines, dilate blood vessels, and modulate T-cell differentiation. LL-37 acts primarily through physical disruption and chemotaxis; VIP operates through G-protein-coupled receptor signaling cascades affecting cAMP levels and gene transcription.
Both peptides appear in immune research, but LL-37 targets microbial membranes and wound healing, while VIP addresses autoimmune conditions, neuroprotection, and vascular tone. The difference between LL-37 and VIP becomes critical when selecting peptides for specific research models. Using one in place of the other negates the intended mechanism entirely.
LL-37: Mechanism, Structure, and Research Applications
LL-37 (leucine-leucine-37) is cleaved from the C-terminal domain of human cathelicidin antimicrobial peptide 18 (hCAP18) by proteinase-3, a serine protease released during neutrophil activation. The mature 37-amino-acid peptide adopts an amphipathic alpha-helical structure. Hydrophobic residues on one face, cationic residues on the other. Allowing it to insert into negatively charged bacterial membranes and form pores that cause osmotic lysis. This mechanism works against Gram-positive bacteria, Gram-negative bacteria, fungi, and enveloped viruses without requiring receptor binding.
Beyond direct antimicrobial activity, LL-37 functions as a chemoattractant for neutrophils, monocytes, and T-cells through formyl peptide receptor-like 1 (FPRL1) and P2X7 purinergic receptor activation. It promotes angiogenesis by binding vascular endothelial growth factor receptor 2 (VEGFR2), accelerates wound closure through keratinocyte migration, and neutralizes bacterial endotoxins like lipopolysaccharide (LPS). Studies published in the Journal of Immunology demonstrated LL-37 concentrations of 5–20 μg/mL effectively killed Pseudomonas aeruginosa and Staphylococcus aureus in vitro while simultaneously dampening excessive inflammatory cytokine release.
Researchers utilize LL-37 in infection models, chronic wound healing studies, and inflammatory bowel disease protocols where both antimicrobial action and immune modulation are required. The peptide's dual functionality. Killing pathogens while recruiting repair cells. Makes it uniquely suited for barrier tissue research. Expression is upregulated during infection, trauma, and UV exposure, suggesting a protective role at epithelial surfaces. Deficiency or dysfunction of LL-37 has been linked to increased susceptibility to skin infections, periodontal disease, and impaired wound healing in clinical observations.
VIP: Mechanism, Structure, and Research Applications
VIP belongs to the secretin-glucagon superfamily of neuropeptides, synthesized as a 170-amino-acid prepro-VIP precursor that's cleaved to the active 28-amino-acid form. It binds two primary G-protein-coupled receptors: VPAC1 (expressed broadly across tissues including lung, liver, intestine, and immune cells) and VPAC2 (concentrated in smooth muscle, central nervous system, and pancreatic beta-cells). Receptor activation stimulates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP) levels, which activates protein kinase A (PKA) and alters gene transcription through cAMP response element-binding protein (CREB).
The primary immunological effect of VIP is suppression of pro-inflammatory cytokines. Specifically tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and IL-12. While promoting anti-inflammatory IL-10 production. A 2005 study in Nature Medicine showed VIP administration reduced disease severity in experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis, by shifting T-helper cell balance from Th1 to Th2 phenotype. VIP also inhibits nuclear factor kappa B (NF-κB) translocation, preventing inflammatory gene activation in activated macrophages and dendritic cells.
Beyond immune regulation, VIP dilates blood vessels through nitric oxide release, relaxes bronchial and intestinal smooth muscle, stimulates pancreatic enzyme secretion, and regulates circadian rhythm via suprachiasmatic nucleus signaling. Researchers studying autoimmune disease, neuroprotection, inflammatory bowel disease, and pulmonary arterial hypertension incorporate VIP into protocols where cytokine modulation and vascular relaxation are mechanistic targets. The peptide's half-life in circulation is brief. Approximately 2 minutes. Due to rapid degradation by proteases, which limits systemic exposure but allows precise temporal control in experimental models.
LL-37 and VIP: Direct Mechanism and Application Comparison
The difference between LL-37 and VIP extends beyond nomenclature into entirely distinct biological roles. LL-37 operates through physical membrane disruption and innate immune recruitment; VIP functions through receptor-mediated signal transduction affecting gene expression and smooth muscle tone. LL-37 is synthesized primarily by neutrophils and epithelial cells at barrier surfaces; VIP is produced by neurons in the peripheral and central nervous systems, as well as immune cells under specific activation states. Their tissue distribution, receptor targets, half-lives, and experimental dosing protocols share no overlap.
Primary Mechanism
Direct membrane disruption via amphipathic alpha-helix insertion; pore formation causes osmotic lysis
VPAC1/VPAC2 receptor binding → cAMP elevation → PKA activation → cytokine modulation and smooth muscle relaxation
LL-37 is structural/physical; VIP is signaling/biochemical. Not interchangeable
Amino Acid Length
37 amino acids, derived from hCAP18 C-terminal cleavage by proteinase-3
28 amino acids, processed from 170-amino-acid prepro-VIP precursor
Different precursor processing and maturation pathways
Target Receptors
FPRL1, P2X7, VEGFR2 (chemotaxis and angiogenesis); no single dedicated receptor for antimicrobial action
VPAC1 (broad tissue), VPAC2 (smooth muscle, CNS). Both Gs-coupled GPCRs
VIP has defined receptor pharmacology; LL-37 acts through multiple low-affinity interactions
Half-Life
Hours to days depending on tissue environment and protease exposure
Approximately 2 minutes in circulation due to rapid enzymatic degradation
VIP requires continuous infusion or frequent dosing; LL-37 persists longer at local sites
Primary Research Use
Antimicrobial studies, wound healing, barrier immunity, chronic infection models
Autoimmune disease, neuroprotection, inflammatory bowel disease, pulmonary hypertension
Choose LL-37 for pathogen defense; VIP for cytokine suppression and vascular modulation
Immune Effect
Recruits neutrophils, monocytes, T-cells; neutralizes endotoxin; promotes tissue repair
Suppresses TNF-α, IL-6, IL-12; increases IL-10; shifts Th1 to Th2 balance
LL-37 activates innate immunity; VIP dampens adaptive immunity
Dosing in Models
5–50 μg/mL in vitro; 1–5 mg/kg subcutaneous or topical in vivo
10–100 nM in vitro; 25–50 μg/kg intravenous or intraperitoneal in vivo
Concentration ranges differ by two orders of magnitude. Protocols are not transferable
Key Takeaways
LL-37 is the only human cathelicidin antimicrobial peptide, functioning through direct pathogen membrane disruption and immune cell chemotaxis via FPRL1 and P2X7 receptors.
VIP is a 28-amino-acid neuropeptide that suppresses pro-inflammatory cytokines by binding VPAC1 and VPAC2 receptors, elevating cAMP, and activating protein kinase A.
The difference between LL-37 and VIP is mechanistic: LL-37 acts physically on membranes; VIP operates through G-protein-coupled receptor signaling cascades.
LL-37 has a half-life measured in hours to days at local tissue sites; VIP degrades within 2 minutes in circulation, requiring continuous infusion for systemic effects.
Research applications diverge completely. LL-37 for antimicrobial defense and wound healing; VIP for autoimmune modulation, neuroprotection, and vascular relaxation.
Real Peptides synthesizes both peptides through small-batch production with exact amino-acid sequencing, ensuring structural integrity and consistent bioactivity across our research-grade peptide collection.
What If: LL-37 and VIP Research Scenarios
What If You're Studying Chronic Wound Healing — Which Peptide Do You Use?
Use LL-37 for wound models where infection risk and epithelial migration are primary variables. LL-37 recruits neutrophils and keratinocytes to the wound bed while killing opportunistic pathogens, addressing both infection control and tissue repair simultaneously. VIP would reduce local inflammation but lacks the antimicrobial and chemotactic functions critical to closure in contaminated or ischemic wounds. The mechanism matters. LL-37's amphipathic structure allows direct interaction with bacterial membranes and extracellular matrix proteins, whereas VIP requires receptor-expressing cells to exert any effect.
What If You're Modeling Autoimmune Encephalomyelitis or Inflammatory Bowel Disease?
VIP is the mechanistically appropriate choice for models where T-cell polarization and cytokine balance drive pathology. The peptide's ability to suppress Th1 cytokines (IFN-γ, TNF-α) while promoting Th2 and regulatory T-cell responses directly addresses autoimmune inflammation. LL-37 would recruit more immune cells to the site. The opposite of therapeutic intent in autoimmune models. Published EAE studies using VIP showed dose-dependent reduction in disease severity, delayed onset, and reduced CNS infiltration; LL-37 has no equivalent data in these models.
What If You're Designing an Infection Model Where Inflammation Needs to Be Controlled?
Combine both peptides if the research question involves simultaneous pathogen clearance and controlled inflammation. LL-37 handles microbial killing through membrane disruption, while VIP prevents the cytokine storm that can cause collateral tissue damage. This dual approach mirrors physiological responses in barrier tissues where both antimicrobial peptides and neuropeptides co-regulate infection outcomes. Dosing would require sequential or staggered administration due to their different half-lives. LL-37 once or twice daily; VIP via continuous low-dose infusion.
The Clear Truth About LL-37 and VIP
Here's the honest answer: LL-37 and VIP aren't alternatives to each other. They don't compete for the same biological role, they don't bind the same receptors, and substituting one for the other in a research protocol means you're no longer studying the mechanism you intended. LL-37 kills pathogens and recruits cells; VIP modulates signaling pathways and suppresses inflammation. If your model requires antimicrobial defense or wound repair, VIP won't deliver those effects no matter how much you use. If your model requires cytokine suppression or vascular relaxation, LL-37 has no receptor-mediated pathway to produce those outcomes.
The confusion exists because both appear in immune-related literature, but appearing in the same research domain doesn't make them interchangeable. One is structural. It physically alters membranes. The other is signaling. It changes gene expression. The difference between LL-37 and VIP is as fundamental as the difference between a detergent and a hormone. Choose based on mechanism, not keyword overlap.
Peptide quality determines experimental reproducibility. Real Peptides guarantees exact amino-acid sequencing and batch-verified purity for both LL-37 and VIP, so the variable you're measuring is the biological effect. Not synthesis inconsistency.
The peptide you select determines the biology you observe. If the research question involves pathogen defense, epithelial repair, or innate immune activation, LL-37 is the tool. If the question involves autoimmune suppression, neuroprotection, or vascular modulation, VIP is the answer. Conflating the two because both relate to immunity is a category error that compromises every downstream result.
Frequently Asked Questions
LL-37 is a 37-amino-acid antimicrobial peptide that disrupts microbial membranes through amphipathic alpha-helix insertion, causing osmotic lysis without requiring receptor binding. VIP is a 28-amino-acid neuropeptide that binds VPAC1 and VPAC2 G-protein-coupled receptors, elevating intracellular cAMP to modulate gene transcription and cytokine production. LL-37 acts through physical membrane interaction; VIP operates through receptor-mediated signal transduction — the mechanisms share no overlap.
No — LL-37 and VIP target completely different biological processes and cannot substitute for each other. LL-37 is used in antimicrobial, wound healing, and innate immunity studies where pathogen clearance and cell recruitment are required. VIP is used in autoimmune, neuroprotection, and inflammatory disease models where cytokine suppression and smooth muscle relaxation are the mechanistic targets. Using one in place of the other negates the intended experimental outcome.
LL-37 is typically dosed at 5–50 μg/mL in vitro and 1–5 mg/kg subcutaneously or topically in vivo, with effects lasting hours to days depending on tissue protease activity. VIP is dosed at 10–100 nM in vitro and 25–50 μg/kg intravenously or intraperitoneally in vivo, but its 2-minute half-life requires continuous infusion or frequent bolus administration for sustained effects. The concentration ranges and delivery methods differ by orders of magnitude.
LL-37 activates innate immunity by recruiting neutrophils, monocytes, and T-cells through FPRL1 and P2X7 receptor signaling, promoting pathogen clearance and tissue repair. VIP suppresses adaptive immunity by inhibiting pro-inflammatory cytokines (TNF-α, IL-6, IL-12) and promoting anti-inflammatory IL-10, shifting T-helper cell balance from Th1 to Th2. LL-37 amplifies immune cell presence at sites of infection; VIP dampens immune cell activation in autoimmune and inflammatory conditions.
LL-37 is the appropriate choice for wound healing models because it provides both antimicrobial action against opportunistic pathogens and chemotactic signals that recruit keratinocytes and fibroblasts to the wound bed. VIP lacks direct antimicrobial activity and does not promote epithelial migration, making it unsuitable for infection-prone or ischemic wound models. The difference in mechanism — LL-37’s physical membrane disruption versus VIP’s receptor signaling — determines functional outcome in tissue repair studies.
VIP is rapidly degraded by circulating proteases including dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP), resulting in a plasma half-life of approximately 2 minutes. LL-37’s alpha-helical structure and cationic charge provide relative resistance to proteolytic cleavage, allowing it to persist for hours at tissue sites where protease concentrations are lower. This difference necessitates continuous infusion for VIP but allows single or twice-daily dosing for LL-37 in experimental protocols.
Both peptides might be combined in infection models where pathogen clearance must occur without excessive inflammatory tissue damage — LL-37 provides antimicrobial defense through membrane disruption while VIP prevents cytokine-mediated collateral damage by suppressing TNF-α and IL-6 release. This mimics physiological conditions at barrier surfaces where antimicrobial peptides and neuropeptides co-regulate infection outcomes. Dosing would require staggered administration due to their vastly different half-lives.
LL-37 does interact with several receptors including FPRL1 (formyl peptide receptor-like 1), P2X7 purinergic receptor, and VEGFR2, but these interactions drive chemotaxis and angiogenesis rather than the intracellular cAMP signaling cascades characteristic of VIP’s VPAC receptor binding. LL-37’s primary antimicrobial mechanism — membrane disruption — does not require receptor binding at all, whereas VIP’s entire function depends on receptor-mediated signal transduction.
VIP is the mechanistically appropriate peptide for autoimmune models because it suppresses Th1-driven inflammation, reduces pro-inflammatory cytokine production, and promotes regulatory T-cell activity through VPAC receptor signaling. Studies in experimental autoimmune encephalomyelitis (the mouse model for multiple sclerosis) demonstrated that VIP administration reduced disease severity and delayed onset. LL-37 would recruit more immune cells to affected tissues, exacerbating rather than alleviating autoimmune pathology.
Synthesis errors or impurities alter the biological activity of both peptides — truncated or misfolded LL-37 loses its amphipathic structure and fails to disrupt membranes, while impure VIP may contain peptide fragments that competitively inhibit VPAC receptors without activating them. Real Peptides guarantees exact amino-acid sequencing and batch-verified purity, ensuring that observed effects reflect the intended peptide mechanism rather than contaminant interference.